10,290
Total Claims
$1.6M
Drug Cost
1,012
Beneficiaries
$1,628
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
+54%
Cost per patient vs peers
$1,628 vs $1,054 avg
+3%
Brand preference vs peers
13.6% vs 13.1% avg
Brand vs Generic
86% generic
Brand: 1,399 claims · $1.5M
Generic: 8,891 claims · $192K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 626 | $559K |
| Riociguat | 24 | $314K |
| Sacubitril/Valsartan | 148 | $151K |
| Rivaroxaban | 132 | $124K |
| Dapagliflozin Propanediol | 99 | $98K |
| Evolocumab | 97 | $59K |
| Ranolazine | 185 | $31K |
| Alirocumab | 34 | $23K |
| Empagliflozin | 21 | $21K |
| Dronedarone Hcl | 16 | $21K |
| Ticagrelor | 35 | $17K |
| Metoprolol Succinate | 883 | $15K |
| Atorvastatin Calcium | 993 | $15K |
| Ezetimibe | 325 | $13K |
| Rosuvastatin Calcium | 683 | $12K |
Prescribing Profile
69
Unique Drugs
$954K
Patient Profile
75
Avg Age
52%
Female
1.64
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About